Low-Dose Naltrexone (LDN): A Physician's Guide

Low-dose naltrexone is one of the more interesting tools in the practice: an old, cheap, FDA-approved medication used at a fraction of its normal dose, with plausible benefit for pain, mood, and the kind of low-grade inflammation that sits underneath a lot of chronic complaints. The honest version is that the science is promising but still young, built mostly on small trials and years of careful clinical use. That combination, low risk and real potential, is why it is worth understanding well.

What Is Low-Dose Naltrexone, and How Is It Different From Regular Naltrexone?

Naltrexone is a medication that has been FDA-approved since the 1980s. At its standard 50 mg dose it blocks opioid receptors for most of the day and is used to treat alcohol use disorder and opioid use disorder. Low-dose naltrexone, or LDN, is the same molecule prescribed off-label at roughly a tenth of that, usually somewhere between 1.5 and 4.5 mg. That tenfold difference in dose changes what the drug does in the body, which is the whole point.

Off-label prescribing is normal, legal medicine when a physician has good reason for it. A large share of what any primary care doctor prescribes is off-label. What matters is that the drug itself is FDA-approved and made by a licensed US pharmacy, the dose is deliberate, and someone is watching how you respond. LDN checks those boxes. It is not a gray-market compound or a research chemical. It is a well-characterized medicine used in a smaller, smarter way.

How Might LDN Actually Work?

There are 2 leading explanations, and they probably work together. The first is the endorphin-rebound idea. When you take a small dose of naltrexone at night, it briefly occupies your opioid receptors for a few hours. The body reads that short blockade as a shortage and responds by making more of its own endorphins and enkephalins, the natural pain-and-mood chemicals. By the time the drug clears, you are left with a higher tide of those compounds. It is a nudge, not a hammer.

The second explanation is more compelling for the conditions people care about. At low doses, naltrexone appears to quiet a set of immune cells in the brain and spinal cord called microglia, in part by blocking a receptor called TLR4. When microglia are stuck in an activated, inflammatory state, they crank out messengers that amplify pain and drag down mood and energy. Calming them down is a reasonable way to explain why LDN shows up in stories about fibromyalgia, autoimmune flares, and brain fog. This is still an area of active research, so I hold it as a working model rather than settled fact.

What Does the Evidence Actually Show?

Here is where tempered confidence matters. LDN has a genuine, growing body of research behind it, but most of it is small pilot trials and open-label studies rather than the large, repeated, placebo-controlled trials that would make it a first-line, guideline-backed therapy. That does not mean it does not work. It means the certainty is modest, and anyone who tells you LDN is a miracle for everything is selling something.

• Fibromyalgia and chronic pain. This is the strongest signal. A pilot study and a later small placebo-controlled crossover trial from Jarred Younger's group at Stanford found meaningful reductions in fibromyalgia pain on LDN compared with placebo. The trials were small, but the effect was real enough to take seriously, and it lines up with what many clinicians see.
• Autoimmune and inflammatory conditions. Small trials by Jill Smith and colleagues suggested LDN could improve active Crohn's disease, and there is scattered evidence and heavy real-world use in conditions like Hashimoto's thyroiditis and other autoimmune states. The data are thin, so LDN is an add-on to real disease-specific treatment, never a replacement for it.
• Multiple sclerosis. A pilot trial led by Bruce Cree found LDN improved quality-of-life measures in MS, though it did not change the disease course. It can help how someone feels, but it is not a substitute for MS therapy.
• Mood and brain fog. The evidence here is the softest and mostly indirect, riding on the anti-inflammatory and endorphin mechanisms. Some patients report clearer thinking and steadier mood, but I frame this as a possible bonus, not a reason to start.

The pattern is consistent: promising, biologically plausible, low-risk, and under-studied. A 2018 review in Medical Sciences summarizing LDN's therapeutic use reached the same measured conclusion.

Who Might LDN Help?

In my practice in Philadelphia, LDN comes up most for people who are stuck. They have chronic widespread pain, a fibromyalgia or chronic fatigue picture, an autoimmune condition that is technically controlled but still leaves them achy and foggy, or a low-grade inflammatory state that has not responded to the obvious moves. Often they have already tried the standard options and either did not tolerate them or did not get enough relief.

LDN is attractive for that group for a plain reason: the downside is small and the cost is low, so a careful trial is a reasonable bet even when the evidence is not airtight. It is not the right tool for acute injury pain, and it is not a longevity supplement to take because it sounds interesting. It earns its place when there is a real inflammatory or central-pain problem to aim at.

What Does a Real LDN Protocol Look Like?

The practical protocol is where most of the value lives, and it is simpler than the internet makes it sound.

Dose range. The working range is 1.5 to 4.5 mg once daily. Many people settle at 4.5 mg, but plenty do best at 3 mg or even 1.5 mg, and a smaller dose that works is better than a bigger one that causes vivid dreams or a wired feeling. Because these are not standard pill strengths, LDN is made by a compounding pharmacy, usually as a capsule or a liquid that makes small adjustments easy.

Titration. You will read about ultra-slow ramps that take months. In my experience that is usually unnecessary. A common, sensible approach is to start at 1.5 mg for a few days to a week, move to 3 mg, and then to 4.5 mg, dosing up to symptom response over roughly 2 weeks. Some people are sensitive and want to go slower, and that is fine, but there is nothing magic about crawling. The goal is to find the lowest dose that helps and stop climbing once you get there.

Timing. LDN has traditionally been taken at bedtime, on the theory that the overnight receptor blockade catches the body's natural endorphin rhythm. The most common early side effect is vivid dreams or lighter sleep for the first week or 2. If that happens and does not settle, moving the dose to the morning works well and does not appear to cost much benefit. Timing is a preference to optimize, not a rule to obey.

Cost and sourcing. LDN is inexpensive. Through a compounding pharmacy it commonly runs somewhere around $30 to $50 a month, and it is not hard to source. That low cost is part of why a short trial is such a low-stakes decision.

What Do Wins Look Like, and When Should You Stop?

A win with LDN usually shows up as less pain, less stiffness, better sleep, steadier mood, or clearer thinking, and it tends to build gradually over weeks rather than switching on overnight. For inflammatory and autoimmune pictures, fewer or milder flares is a meaningful signal even when day-to-day pain moves slowly. I ask people to track 1 or 2 things that matter to them, a pain score, morning stiffness, energy at 3 pm, so we are judging the trial on something concrete instead of a vague sense.

Knowing when to stop is just as important as knowing when to start. If someone has reached 4.5 mg, or the highest dose they tolerate, and gotten no clear benefit after about 8 to 12 weeks, LDN is probably not their answer and we stop. There is no case for endlessly escalating the dose or waiting half a year for something to appear. When it works, people usually know within a couple of months. When it does not, the low cost and clean stop mean we have lost very little by trying.

Is LDN Safe, and What Are the Cautions?

LDN has a reassuring safety profile at these doses, which is a big part of its appeal. The common side effects are mild and usually temporary: vivid dreams, lighter sleep, occasional headache, or some early stomach upset. Most of these fade in the first week or two or resolve with a smaller dose or a timing change.

The one hard rule is opioids. Because naltrexone blocks opioid receptors, it does not mix with opioid pain medications. It will block their effect, and starting it while someone is physically dependent on opioids can trigger withdrawal. Anyone taking prescription opioids needs to be off them for about 7 to 10 days before starting LDN, and that has to be planned with a physician. LDN also deserves a conversation if you have significant liver disease, are pregnant or trying to conceive, or take other medications that interact. None of this is exotic, and all of it is why LDN should be physician-guided rather than ordered on your own from an online pharmacy.

How Does Fishtown Medicine Approach LDN?

At Fishtown Medicine, LDN fits the way the whole practice works: figure out what is actually going on, match the tool to the person, and stay in the loop while we see if it helps. Because Fishtown Medicine is a direct primary care practice built around access, that follow-up is easy - a quick message when the dreams are annoying, a dose tweak without a copay or a 3-week wait for an appointment. As a mobile-first practice serving Greater Philadelphia through home visits and secure messaging, phone, and video, Dr. Ash can start LDN, adjust it, and check in without turning it into a production.

The frame is physician oversight and a clear-eyed trial. Dr. Ash will tell you plainly that the evidence is promising rather than proven, help you decide whether a trial makes sense for your situation, set a clear plan for what a win looks like and when to stop, and make sure it plays well with the rest of your medications and your other care. That is the difference between a thoughtful trial of a low-risk medicine and guessing.

Related at Fishtown Medicine

• Peptide Therapy: What Patients Should Know - how Fishtown Medicine thinks about promising-but-unproven therapies and honest physician oversight
• Emotional Health - the deeper read on mood, inflammation, and the mind-body picture LDN may touch
• Leaky Gut and Intestinal Permeability - the inflammatory and autoimmune terrain where LDN often comes up
• Curcumin (Turmeric) Clinical Guide - another low-risk, anti-inflammatory tool for pain and joints
• Back Pain and Sciatica in Philadelphia - the broader approach to chronic pain when the obvious fixes have not worked
• Sauna Therapy Clinical Guide - a companion approach for pain, mood, and inflammation